Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MITF | O75030 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13732440 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL372886 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| Potassium Ion SCHEMBL3805984 | 0.97 | SMN1; SMN2 (0.95) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL703829 | 0.92 | SMN1; SMN2 (0.85) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL703830 | 0.92 | SMN1; SMN2 (0.85) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL6152811 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL6152809 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL20959749 | 0.82 | ALDH1A1 (0.71) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL1331513 | 0.82 | ALDH1A1 (0.71) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL1331516 | 0.82 | ALDH1A1 (0.71) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2431037-B1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof | ATTENUA INC (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2465501-B1 | Method for the preparation of (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide | ATTENUA INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20150045386-A1 | (2S,3R)-N-2-3-PYRIDINYLMETHYL-1-AZABICYCLO 2.2.2 OCT-3-YL BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | ATTENUA, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8846715-B2 | (2S,3R)-N-(2((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide novel salt forms, and methods of use thereof | TARGACEPT, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140128606-A1 | ANTIPRURITIC AGENT | TORAY INDUSTRIES, INC. (JP) | 2014-05-08 | — | — | US | disclosed |
| US-20140128606-A1 | ANTIPRURITIC AGENT | TORAY INDUSTRIES, INC. (JP) | 2014-05-08 | — | — | US | disclosed |
| US-20140128606-A1 | ANTIPRURITIC AGENT | TORAY INDUSTRIES, INC. (JP) | 2014-05-08 | — | — | US | disclosed |
| EP-2727604-A1 | ANTIPRURITIC AGENT | Toray Industries, Inc. (JP) | 2014-05-07 | — | — | EP | disclosed |
| EP-2727604-A1 | ANTIPRURITIC AGENT | Toray Industries, Inc. (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-7425561-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080138287-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF | ATTENUA, INC. | 2008-06-12 | — | — | US | disclosed |
| EP-1594869-B1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT INC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070197579-A1 | Heteroaryl-Substituted Diazatricycloalkanes and Methods of Use Thereof | TARGACEPT, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20060247270-A1 | e.g. 2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl N-phenylcarbamate; nicotinic acetylcholine receptors alpha 7 (nAChRs)/neurotransmitter modulator; diagnostic radiolabel; central nervous systrem disorders, autoimmune diseases; antiinflammatory, antitumor agents, angiogenesis inhibitor | ATTENUA, INC. | 2006-11-02 | — | — | US | disclosed |
| US-20050255040-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2005-11-17 | — | — | US | disclosed |
| US-6953855-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2004-01-01 | — | — | US | disclosed |
| US-20030045523-A1 | Nicotinic cholinergic receptor antagonists | SCHMITT JEFFREY DANIEL (US) | 2003-03-06 | — | — | US | disclosed |
| US-6432975-B1 | AROMATIC ALKYLENE AZOBICYCLIC COMPOUNDS AS NICOTINIC RECEPTOR ANTAGONISTS; ANTIDEPRESSANTS; NERVOUS SYSTEM DISORDER TREATMENT | TARGACEPT, INC. | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138287-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | SMN1; SMN2 3054/4885ALDH1A1 880/4885KDM4E 1568/4885 |
| US-20030045523-A1 | Nicotinic cholinergic receptor antagonists | CHRNG, CHRNB1, CHRNA1 | SMN1; SMN2 2009/4885ALDH1A1 1668/4885KDM4E 1520/4885 |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | CHRNA7, CHRNA2, CHRNA4 | SMN1; SMN2 525/4885ALDH1A1 1381/4885KDM4E 3190/4885 |
| US-20070197579-A1 | Heteroaryl-Substituted Diazatricycloalkanes and Methods of Use Thereof | CHRNA7, CHRNA1, CHRNE | SMN1; SMN2 3797/4885ALDH1A1 1733/4885KDM4E 2061/4885 |
| US-20060247270-A1 | e.g. 2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl N-phenylcarbamate; nicotinic acetylcholine receptors alpha 7 (nAChRs)/neurotransmitter modulator; diagnostic radiolabel; central nervous systrem disorders, autoimmune diseases; antiinflammatory, antitumor agents, angiogenesis inhibitor | CHRM1, CHRNA7, CHRM3 | SMN1; SMN2 1217/4885ALDH1A1 1672/4885KDM4E 1584/4885 |
| US-20150045386-A1 | (2S,3R)-N-2-3-PYRIDINYLMETHYL-1-AZABICYCLO 2.2.2 OCT-3-YL BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | HCN3, HCN2, NTSR2 | SMN1; SMN2 117/4885ALDH1A1 913/4885KDM4E 1626/4885 |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | CHRNA7, CHRNA3, CHRNA1 | SMN1; SMN2 3112/4885ALDH1A1 1036/4885KDM4E 1804/4885 |
| US-20140128606-A1 | ANTIPRURITIC AGENT | MRGPRX2, HRH4, TRPV1 | SMN1; SMN2 2608/4885ALDH1A1 4074/4885KDM4E 4676/4885 |
| US-20050255040-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | CHRNA7, CHRNA3, CHRNA5 | SMN1; SMN2 3222/4885ALDH1A1 882/4885KDM4E 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.